Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To confirm appropriate dose levels of fitusiran when administered to male pediatric
participants (ages 1 to <12 years of age) with severe hemophilia A or B
Secondary Objective:
- To characterize the safety and tolerability
- To determine fitusiran plasma concentrations at selected time points